Introduction
Human epidermal growth factor receptor 2 (HER2) is a transmembrane receptor tyrosine kinase (RTK) and a member of the HER family that includes HER1, known as epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 3 (HER3), and human epidermal growth factor receptor 4 (HER4). It controls growth, differentiation, and cell survival through dimerization with other HER receptors, most notably HER3 and EGFR. HER2-dependent signaling is mediated by various downstream pathways, all of which include activation of multiple intracellular effectors, such as mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/Akt [
1]. HER2 amplification occurs in approximately 25% of breast cancers and correlates with a poor prognosis and resistance to conventional antitumor therapies [
2,
3]. However, it is also an important target for anti-HER2 drugs, namely, monoclonal antibodies that target the extracellular domain of the receptor, such as trastuzumab and pertuzumab, small-molecule adenosine triphosphate (ATP) competitors able to block tyrosine kinase (TK) activity within the intracellular domain of HER2, such as lapatinib, and antibody-drug conjugates such as trastuzumab emtansine [
4,
5]. Lapatinib, a dual inhibitor able to target also the TK domain of HER1 [
6,
7], has been approved for the treatment of patients with HER2-positive metastatic breast cancer after trastuzumab failure. When given in combination with capecitabine, this agent significantly improves time to progression [
8]. Combined with paclitaxel, lapatinib is active as first-line treatment [
9]. Unfortunately, some patients are constitutively resistant to lapatinib treatment, and, even in responders, the disease often progresses because of the selection of tumor cells that have acquired resistance to the drug.
Resistance to lapatinib occurs via various mechanisms: HER2 alterations, aberrant activation of escape pathways mediated by other RTKs or intracellular signaling effectors, co-expression of the truncated p95 HER2 receptor [
9], and changes in apoptosis or cell-cycle regulation. Based on these findings, various therapeutic approaches are being investigated in the attempt to overcome resistance to lapatinib in breast cancer patients [
10].
Src family kinases are nonreceptor TKs that interact with several transmembrane receptors, including members of the HER family, insulin-like growth factor-1 receptor, and c-Met. Through these interactions, Src controls cell growth and survival by modulating the activity of such intracellular effectors as PI3K/Akt and signal transducer and activator of transcription 3 (STAT3) [
11]. Src also is involved in the phosphorylation of focal adhesion kinase (FAK), paxillin, RhoA, and other molecules, and therefore it is implicated in the regulation of cancer cell migration and invasion [
12]. Src activation has been described as a determinant of resistance to anti-EGFR drugs in human lung, colorectal, and pancreatic cancer cell models [
13‐
15]. For example, Src contributes to c-Met activation in gefitinib-resistant non-small cell lung cancer cells [
16]. Moreover, Src activation has been associated with resistance to the anti-HER2 drugs trastuzumab [
17] and lapatinib [
18] in HER2-overexpressing breast cancer cells. Despite the large body of data on the interactions between Src and HER2 in breast cancer [
19‐
21], it is still unclear how Src activation is able to trigger and sustain resistance to anti-HER2 antagonists.
In this study, we investigated the role of Src in intrinsic and acquired lapatinib resistance in human breast cancer cell lines overexpressing HER-2, both in vitro and in vivo. We also evaluated the effects of the Src inhibitor saracatinib (AZD0530), alone and combined with lapatinib, as a therapeutic strategy in breast cancer models resistant to lapatinib.
Materials and methods
Compounds and cell cultures
Lapatinib and saracatinib were purchased from Selleck Chemicals, Munich, Germany. Cetuximab was provided by ImClone Systems NJ, USA. Human breast cancer cell lines MDA-MB-361, SKBR-3, and BT474 were obtained from the American Type Culture Collection. The KPL4 cell line was isolated from the malignant pleural effusion of a breast cancer patient with an inflammatory skin metastasis; these cells are resistant to trastuzumab in female athymic nude mice [
22]. The JIMT-1 cell line was established from a pleural metastasis of a 62-year-old breast cancer patient who was clinically resistant to trastuzumab.
Ethical approval by the local ethical committees and patient consent were obtained for the use of KPL4 and JIMT-1 cells. Ethical approval was obtained from the University of Tampere and Tampere University Hospital, Finland, for the JIMT-1 cells. Use of the KPL4 cells was approved by the Kawasaki Medical School, Kurashiki, Okayama, Japan. JIMT-1 cells form trastuzumab-resistant xenograft tumors in nude mice [
23]. MDA-MB-361 lapatinib-resistant (LR) cells were generated by using a validated protocol of
in vivo/
in vitro selection after prolonged exposure to the drug [
24]. All cell lines were authenticated by using DNA fingerprinting and maintained in RPMI medium supplemented with 10% heat-inactivated fetal bovine serum, 20 m
M HEPES, pH 7.4, penicillin (100 IU/ml), streptomycin (100 μg/ml), and 4 m
M glutamine (ICN, Irvine, UK) in a humidified atmosphere of 95% air and 5% CO
2 at 37°C.
MTT survival assay
Cells (104 cells/well) were grown in 24-well plates and exposed for 72 hours to increasing doses of lapatinib, saracatinib, cetuximab, or their combinations. The percentage of cell survival was determined by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT). The half-maximal inhibitory concentration (IC50) for each drug was calculated by GraphPad Prism 5.0 software, normalizing the response between 0 and 100%.
Wound-healing assay
Cancer cell-line monolayers grown to confluence on gridded plastic dishes were wounded by scratching them with a 200-μl pipette tip, and then grown in the presence or absence of each drug (saracatinib, lapatinib, or cetuximab) alone or in combinations. The wounds were photographed (10× objective) at 0 and 24 hours, and healing was quantified by measuring the distance between the edges of the wound by using Adobe Photoshop (v. 8.0.1; Adobe Systems, Inc., San Jose, CA, USA). The results are reported as the percentage of the total distance of the original wound enclosed by cells.
Invasion assay
The invasive potential of cancer cells was determined by using a model based on co-culture with fibroblasts, as previously described [
25]. In brief, fibroblasts were seeded (10
4 cells/well) in 24-well plates. After confluence, cells were permeabilized with dimethyl sulfoxide (DMSO; 500 μl) and subsequently overlaid with tumor cells. One hour later, the individual wells were treated with saracatinib, lapatinib, or cetuximab, or their combinations. Eighteen hours later, cells were incubated for 15 minutes with 0.2% trypan blue/phosphate-buffered saline (Mediatech, Herndon, VA, USA). To measure invasion, cells were lysed with 100 μl of 1% sodium dodecyl sulfate/phosphate-buffered saline. Absorbance was measured with a microplate Synergy HT-Bioteck at 610 nm and compared with the absorbance of fibroblasts not overlaid with tumor cells. The results were expressed as percentage of invasion of the fibroblast monolayer with the following formula: X = 100% (cell line and fibroblast well absorbance/fibroblast well absorbance) [
25].
Immunoprecipitation and Western blot analyses
Total cell lysates from cell cultures or tumor specimens were resolved by 4% to 15% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and probed with anti-human antibodies (see Additional file
1). Co-immunoprecipitation analyses were performed with anti-Src, anti-HER2, or anti-EGFR antibodies; membranes were blotted with anti-Src, anti-HER2, anti-EGFR, or anti-HER3 antibodies. The total lysate from BT474 cells served as positive control. Immunoreactive proteins were visualized by enhanced chemiluminescence (Pierce, Rockford, IL, USA). Densitometry was performed with Image J software (NIH, Bethesda, MD, USA). Details of the complete procedure are reported in Additional file
1.
RNA interference
Small interfering RNA (siRNA) against EGFR and Src were obtained from Invitrogen Life Technologies and Ambion Life Technology (Grand Island, NY, USA), respectively. A nonsense sequence was used as negative control. Details of the complete procedure are reported in Additional file
1.
Transfection of human EGFR and EGFR-Tyr845Phe
Human wild-type EGFR or mutant EGFR-Tyr845Phe (Y845F) was cloned into a pcDNA vector. MDA-MB-361 cells were transiently transfected by using the Lipofectamine 2000 reagent (Invitrogen), according to the manufacturer’s instructions. Twenty-four hours after transfection, the cells were treated with lapatinib (0.2 μM) for 3 consecutive days and analyzed with MTT assay.
Nude mice cancer xenograft models
Five-week-old Balb/c athymic (nu+/nu+) mice (Charles River Laboratories, Milan, Italy), maintained in accordance with the guidelines of the University of Naples “Federico II” Animal Care Committee (ethical approval protocol number 65), were injected orthotopically in the fourth mammary fat pad, with JIMT-1 cells (10
7 cells/mouse) resuspended in 200 μl of Matrigel (CBP, Bedford, MA, USA). Seven days later, when tumors became detectable, mice (10/group) were randomized to receive lapatinib, 100 mg/kg intraperitoneally (i.p.) 5 times per week for 3 weeks; saracatinib, 50 mg/kg via oral gavage 5 times per week for 3 weeks; cetuximab, 10 mg/kg i.p. twice a week for 3 weeks, or their combinations. Animals treated with dimethyl sulfoxide (DMSO) vehicle served as controls. Tumor volume (cm
3) was measured by using the formula π/6 × largest diameter × (smallest diameter)
2[
26].
Before inoculation with JIMT-1 cells, mice (six mice/group) were treated with lapatinib (100 mg/kg, i.p.), saracatinib (50 mg/kg
per os) or both for a week. Then 30 × 10
5 cells were injected into each animal’s tail vein, after which mice were treated with lapatinib, saracatinib, or both for 7 consecutive days. All mice were killed 21 days after the injection of tumor cells [
27]. Human DNA in all lobes of the lungs of the mice was measured by quantifying
Alu sequences by polymerase chain reaction, as described elsewhere [
28] and detailed in Additional file
1.
Statistical analysis
The results of in vitro experiments were analyzed with Student t test and expressed as means and standard deviations (SDs) for at least three independent experiments performed in triplicate. The statistical significance of tumor growth was determined by one-way ANOVA and the Dunnett multiple comparison posttest, whereas the log-rank test was used to determine the statistical significance of mouse survival. All reported P values were two-sided. Analyses were performed with the BMDP New System statistical package version 1.0 for Microsoft Windows (BMDP Statistical Software, Los Angeles, CA, USA).
Discussion
This study implicates functional crosstalk between EGFR and Src in the onset of lapatinib resistance. The combination of lapatinib with the Src inhibitor saracatinib prevented not only the proliferation and survival of breast cancer cells, but also cell motility, migration, and invasion. These changes may impair the metastatic spread. We showed that treatment with saracatinib plus lapatinib reduced the formation of lung metastases in nude mice injected with lapatinib-resistant breast cancer cells. Consistently, the combined treatment suppressed signaling pathways that mediate both cell proliferation (PI3K/Akt and MAPK) and motility (FAK, paxillin, and p130Cas).
More interestingly, Src was overexpressed, and it preferentially bound to and activated EGFR in lapatinib-resistant models, as demonstrated by the increased levels of phosphorylation at the Y845 tyrosine residue of the receptor in both JIMT-1 and MDA-MB-361-LR cells. EGFR Y845 is a conserved tyrosine within the kinase domain in most RTKs, and it plays an important role in the biologic synergy and cross-talk of EGFR/Src [
34]. In addition, phosphorylation of Y845 on EGFR is required for cell growth and transformation in breast cancer cell lines [
37]. The importance of EGFR-dependent signaling in HER2 resistance also emerges from the finding reported by Rexer
et al.[
38] that BT474 cells, stably transfected with the increased autocatalytic T798M variant of the HER2 receptor, display increased expression of EGFR ligands and are efficiently inhibited by the combination of cetuximab and trastuzumab.
It has recently been suggested that acquired resistance to lapatinib could be sustained by activation of an HER3/EGFR-dependent pathway that is related to heregulin stimulation [
39], thereby implicating HER family receptors other than HER2 in lapatinib resistance. We can rule out that HER3 was involved in our models of lapatinib resistance because it did not interact significantly with either EGFR or Src.
The alternative activation of RTKs other than HER3 has been described as a mechanism of resistance to tyrosine kinase inhibitors [
40], and it could, at least in some preclinical models, depend on Src activity. In breast cancer cells, Met and Src were found to cooperate to overcome gefitinib-induced EGFR inhibition [
41]. In addition, about 20% of human breast cancers overexpress EGFR and Src, which suggests that both kinases contribute to breast cancer progression [
33]. In a very recent study, levels of the chemokine receptor type 4 were reported to be higher in SKBR-3 cells with acquired resistance to lapatinib than in parental cells, and this was coupled with persistent levels of extracellular signal-regulated kinases 1/2 (ERK1/2) and AKT activation [
42]. Moreover, some activating mutations in the catalytic subunit of PI3K could confer resistance to lapatinib, thus requiring a dual PI3K/HER2 blockade [
43]. Taken together, these data indicate that multiple alterations could arise in lapatinib-resistant cells, and that robust inhibition of cancer cell proliferation could be achieved by simultaneously blocking signaling pathways mediated by different RTKs.
Here we demonstrated that, in cellular models of lapatinib resistance, inhibition of HER2 or EGFR induced by single-agent therapy did not exert any relevant biologic effect, whereas the combination of lapatinib and cetuximab inhibited proliferation, migration, and invasion that, in turn, seem to depend on Src activation. Inhibition of HER2 alone is ineffective due to the sustained Src-mediated EGFR activation, which is reflected by high levels of pAkt and pMAPK in resistant cells after lapatinib treatment. Our data suggest that, in acquired or constitutive resistance to lapatinib, EGFR could drive alternative escape pathways. In this context, lapatinib acts mainly as an HER2 inhibitor without affecting EGFR phosphorylation, which is sustained by Src overactivation.
The role of EGFR-dependent and HER2-dependent signaling in lapatinib resistance is also demonstrated by the finding that cetuximab alone is not able to circumvent resistance because of the presence of a still-active HER2 receptor. Consistently, the addition of Src inhibition to cetuximab does not revert the resistant behavior, whereas simultaneous blockade of EGFR and HER2 does. The combination of cetuximab with lapatinib is extremely active, both
in vitro and
in vivo, in reducing signaling transduction under the control of these two cooperating receptors. These findings are consistent with the observation that depletion of EGFR by siRNA knockdown does not affect sensitivity to lapatinib in HER2-overexpressing cells [
44] and explains the differential effect of cetuximab treatment. The anti-EGFR mAb binds the extracellular domain of the receptor by competing with ligand binding, and by inducing receptor internalization and consequent degradation [
36], thus reducing EGFR activation more efficiently than lapatinib.
Our data could have clinical implications because co-expression of EGFR and HER2 has been observed in 10% to 36% of primary human breast carcinomas, and it is generally associated with a poorer prognosis compared with breast carcinomas expressing a single receptor [
45]. In addition, survival is shorter in breast cancer patients expressing phosphorylated HER2 or both HER2 and EGFR [
46].
Acknowledgements
This study was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC) My First Grant 2011–2014 (MFAG-11473) to RB. KPL-4 human breast cancer cells were kindly provided by Prof. J Kurebayashi (Kawasaki Medical School, Kurashiki, Japan). JIMT-1 human breast cancer cells were kindly provided by Prof. J Isola (Institute of Medical Technology, University and University Hospital of Tampere, 33520 Tampere, Finland). Dr Giuseppe Pignataro (Department of Neuroscienze e Scienze Riproduttive ed Ontostomatologiche, University Federico II of Naples, Italy) acted as a pharmacokinetic consultant. Jean Ann Gilder (Scientific Communication srl., Naples, Italy) edited and revised the text for language and clarity.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LF and LN performed in vitro studies, nude mouse xenograft experiments, and data analysis, and wrote the manuscript. RM, CDA, and VDA performed the statistical analysis. LR and RR contributed to in vitro assays. FI, GT, and AS helped in the nude mouse xenograft experiments. RB, BMV, and SDP conceived and designed the study. SJP provided reagents, reviewed the manuscript, and offered experimental suggestions. RB prepared the manuscript with LF and LN and allocated funding for the work. RB and SDP critically revised the manuscript and provided scientific direction. All authors read, revised critically for intellectual content, and approved the final manuscript. All authors agreed with the accuracy and integrity of any part of the work.